# Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

> **NCT06675123** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** BTK Inhibitor
- **PROCEDURE:** Computed Tomography
- **DRUG:** Pacritinib
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06675123
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-03-08
- **Final completion:** 2028-03-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06675123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06675123, "Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06675123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*